Chang CC, Lo SW, Chang HC, Song J, et al. CTLA-4 inhibitors are associated with a higher risk of cardiovascular events than PD-1 inhibitors in Patients with Melanoma. J Am Acad Dermatol 2025 Feb 27:S0190-9622(25)00370.
PMID: 40023406